EARLY BREAST CANCER
Clinical trials for EARLY BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new EARLY BREAST CANCER trials appear
Sign up with your email to follow new studies for EARLY BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Biosimilar breast cancer drug trial pulled before it began
Disease control TerminatedThis study aimed to compare a biosimilar version of pertuzumab (EG1206A) to the original drug (Perjeta) in people with HER2-positive, hormone receptor-negative early breast cancer. Participants would have received either drug alongside trastuzumab and chemotherapy before surgery,…
Matched conditions: EARLY BREAST CANCER
Phase: PHASE3 • Sponsor: EirGenix, Inc. • Aim: Disease control
Last updated Jun 23, 2026 20:48 UTC
-
Could a lighter chemo regimen beat standard treatment for HER2+ breast cancer?
Disease control OngoingThis phase II study tests a de-escalated chemotherapy regimen (paclitaxel, trastuzumab, and pertuzumab, or THP) in 93 patients with early HER2-positive breast cancer, comparing it to a historical control group of 93 patients who received the standard TCHP regimen. The goal is to …
Matched conditions: EARLY BREAST CANCER
Phase: PHASE2 • Sponsor: National Medical Research Radiological Centre of the Ministry of Health of Russia • Aim: Disease control
Last updated Jun 23, 2026 12:09 UTC
-
Chemo-Free hope: new drug combo targets HER2 breast cancer
Disease control OngoingThis phase 2 trial is testing whether a combination of targeted drugs (trastuzumab, pertuzumab, and T-DM1) can treat HER2-positive early breast cancer without standard chemotherapy. About 393 patients will receive these drugs before surgery to see if the cancer disappears complet…
Matched conditions: EARLY BREAST CANCER
Phase: PHASE2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 22, 2026 11:58 UTC
-
New hope for High-Risk breast cancer: drug combo may keep cancer away
Disease control OngoingThis study looks at women with a high-risk type of breast cancer (HR+/HER2-) who have finished initial treatments like surgery or chemo. Researchers want to see if adding the drug abemaciclib to standard hormone therapy helps keep the cancer from coming back better than hormone t…
Matched conditions: EARLY BREAST CANCER
Phase: PHASE3 • Sponsor: West German Study Group • Aim: Disease control
Last updated Jun 18, 2026 11:47 UTC
-
Major trial tests promising pill to stop breast cancer comeback
Disease control OngoingThis large phase 3 study tests whether adding the drug ribociclib to standard hormone therapy can help prevent breast cancer from coming back in people with early-stage hormone receptor-positive, HER2-negative breast cancer. Over 5,000 women and men took part. The goal is to see …
Matched conditions: EARLY BREAST CANCER
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 18, 2026 11:46 UTC
-
New pill combo could replace chemo for some breast cancer patients
Disease control OngoingThis study tests whether a combination of two pills (letrozole and abemaciclib) works as well as standard chemotherapy before surgery in women with a common type of early breast cancer (HR-positive, HER2-negative) that is at high or intermediate risk of coming back. About 200 wom…
Matched conditions: EARLY BREAST CANCER
Phase: PHASE2 • Sponsor: Spanish Breast Cancer Research Group • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
Hope for motherhood: study tests pausing breast cancer meds for pregnancy
Disease control OngoingThis study looks at whether young women with early-stage, hormone-sensitive breast cancer can temporarily stop their hormone therapy to try to get pregnant without raising their risk of cancer coming back. It involves 518 women aged 18 to 42 who have already been on hormone thera…
Matched conditions: EARLY BREAST CANCER
Phase: NA • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC
-
AI may predict breast cancer return better than current methods
Knowledge-focused OngoingThis study looks at whether an artificial intelligence (AI) program can accurately predict if early-stage breast cancer will come back in a different part of the body. Researchers will analyze tissue samples and health records from 2,200 women who were previously treated for ER-p…
Matched conditions: EARLY BREAST CANCER
Sponsor: Spotlight Medical • Aim: Knowledge-focused
Last updated Jun 01, 2026 17:55 UTC